11 Sep

Why Does Jim Cramer Like Cronos Group and Aphria?

WRITTEN BY Sushree Mohanty

Jim Cramer is very vocal about his choices in the cannabis sector. Cannabis is a hot sector right now! In August, he mentioned that the cannabis sector is back in action after a disastrous July.

Why Does Jim Cramer Like Cronos Group and Aphria?

Jim Cramer’s top picks

Previously, I discussed why Jim Cramer, the widely followed host of CNBC’s Mad Money, favored Canopy Growth and Cronos Group (CRON) in August. Later, he chose Cronos Group and Aphria (APHA). Notably, Cramer dropped Canopy Growth (CGC) (WEED) from his top picks. Canopy Growth reported disappointing results for the first quarter of 2020. The results made Cramer change his opinion about the stock. Last month, we discussed why Cramer chose Cronos Group and Aphria. Let’s review his choices in more detail.

Why does Jim Cramer like Cronos Group?

Cronos Group showed tremendous potential in the last quarter. The company’s revenues rose 120% YoY to $10.2 million Canadian dollars.  Cronos Group’s earnings and revenues beat the estimates. However, the company reported a negative EBITDA of $17.7 Canadian dollars. Earlier, I discussed how a negative EBITDA implies that a company’s operating costs are higher. Aurora Cannabis (ACB) expects to report a positive EBITDA in its fourth-quarter results.

Cronos Group got a boost after Altria invested 2.4 million Canadian dollars in the company. Since Altria is the largest shareholder, the company’s growth prospects look better. Recently, Cronos Group acquired Redwood Holding Group to expand its hemp business in the US. An Investorplace article discussed why Cronos Group is better at handling its debt compared to Canopy Growth. Cronos Group chose to pay $225 million out of the $300 million to buy RedWood. Paying in cash looked like a wise decision to lower the debt load. Cronos Group’s long-term debt is about $15 million—compared to Canopy Growth’s debt load of $700 million.

Cronos Group’s outlook for 2019

The company’s prospects look positive for 2019. Analysts expect Cronos Group to generate revenues of 60.1 million Canadian dollars in 2019. The estimate reflects 283% growth YoY. According to analysts’ estimates, the company could also report a profit of $1.20 Canadian dollars per share in 2019 compared to a loss of $0.11 Canadian dollars in 2018. Read Cronos: What’s the Word on Wall Street? to learn more about the company’s outlook. Cronos Group also plans to expand its edible business after Canada legalizes edibles next month. To learn more, read Cannabis 2.0 Legalization: Canada Is Ready.

Meanwhile, vaping concerns by Health Canada could be a challenge for Cronos Group’s vaporizing category. The company opened a cannabinoid device research and development facility in Israel to produce next-generation vaporizer products. However, due to a lack of details on the regulations front, it’s hard to estimate the segment’s growth.

To learn more about Cronos Group’s valuation, read Tilray and Cronos Group: A Valuation Update.

Why does Jim Cramer like Aphria? 

The marijuana sector struggled in the past few months after getting swallowed up in regulation scandals. The struggle shows that regulations are important in the cannabis industry. Aphria’s upbeat earnings results restored investors’ faith in the cannabis sector. I’m not surprised that Jim Cramer picked Aphria. The company’s net revenues rose 75% YoY for the fourth quarter. The revenues for adult-use cannabis increased 158% YoY. Aphria also reported a positive EBITDA of 0.209 million Canadian dollars. The company’s fiscal 2020 guidance looks positive. To learn more about the company’s outlook, read Aphria Has Analysts Feeling Optimistic—Here’s Why.

Stock performance and target price

Cronos Group has gained 6.4% in September, while Aphria has gained 11.6%. Both of the stocks have gained 12.8% and 22.8% YTD. In contrast, Canopy Growth has gained 16.3% in September and 2.0% YTD.

Cronos Group’s target price is set at 19.8 Canadian dollars, which is 29% higher than its last closing price. Aphria’s target price is set at 14.9 Canadian dollars, which represents a 64% upside for the stock. Meanwhile, Canopy Growth’s target price is set at 55.7 Canadian dollars, which is 55% more than its closing price.

What to expect in September

So far, September looks favorable for the cannabis industry. The last few months were challenging for the sector. Regulatory scandals and Canopy Growth’s disastrous results pulled down the whole sector. However, with the cannabis legalization topic heating up, the cannabis sector is gaining traction.

The North American industry is tracked by the Horizons Marijuana Life Sciences ETF (HMMJ). HMMJ has gained 6.0% in September and 4.5% YTD.

To learn more about the global cannabis industry, read Cannabis: While the US Waits, the World Opens Up.

Stay with us to get regular updates on the cannabis industry.

Latest articles

Harvest Health (HARV) reported its Q3 earnings yesterday. HARV posted revenue of $33.15 million, which was lower than analysts' estimate of $34.18 million.

Apple (AAPL) stock is up almost 68% year-to-date. AAPL has returned 50% in the trailing 12 months and 125% in the last five years.

While the media caters to Millennial preferences, there’s one economic sector that’s shifting to a more seasoned crowd: healthcare stocks.

Despite solid earnings growth this year, Energy Transfer stock fell close to its multiyear lows recently. Could this weakness be seen as an opportunity?

Last week, Duquesne Family Office, managed by Stanley Druckenmiller, filed its Q3 13F with the SEC. We'll look at the fund's top holdings, buys, and sells.

Investors have waited for a peek at Tesla's electric pickup truck. Elon Musk hinted that it has the Porsche 911's performance and the F-150's functionality.